Micofenolato De Mofetil Aristo

Mycophenolate Mofetil, the active ingredient in Micofenolato De Mofetil Aristo, is an immunosuppressant presented as an oral formulation for oral use. It is employed to prevent organ transplant rejection and to treat lupus nephritis in adult patients.

GNH USA supplies Micofenolato De Mofetil Aristo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution, including batch release certificates and stability data, to ensure compliance.

Mycophenolate Mofetil is an antimetabolite immunosuppressant used in specific transplant and autoimmune conditions.

- Organ transplant rejection: helps prevent acute graft rejection and maintain graft survival. - Lupus nephritis: reduces proteinuria and preserves kidney function in patients with systemic lupus erythematosus. - Kidney transplant: supports long‑term graft acceptance and decreases incidence of chronic rejection.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, sometimes watery. - Vomiting: occasional emesis. - Abdominal pain: cramping or discomfort. - Headache: mild to moderate. - Infections: increased susceptibility to viral or bacterial infections.

Serious or Rare Side Effects: - Leukopenia: significant drop in white blood cells. - Anemia: reduced red blood cell count. - Severe infections: opportunistic or systemic infections. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Malignancy risk: potential increased risk of certain cancers. - Teratogenicity: fetal harm if exposure occurs during pregnancy.

Patients should be monitored closely for safety and efficacy.

- Monitor blood counts: regular CBC to detect leukopenia or anemia. - Monitor liver function: periodic LFTs for hepatic safety. - Avoid in pregnancy: contraindicated due to teratogenic risk; ensure effective contraception. - Use caution in renal impairment: dose adjustment may be required. - Counsel on infection risk: advise prompt reporting of fever or signs of infection. - Store below 25°C: keep in the original pack, protect from moisture.

Mycophenolate Mofetil may interact with several medicines.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression. - Cyclosporine: increased mycophenolate exposure, risk of toxicity. - Tacrolimus: similar risk of heightened exposure. - Ribavirin: enhanced hematologic toxicity. - Live vaccines: risk of uncontrolled infection.

Moderate Interactions (Monitor Closely): - Antacids: may reduce absorption; separate dosing. - Cholestyramine: can bind drug, lowering efficacy. - Warfarin: potential alteration of INR; monitor coagulation. - Phenytoin: may affect drug metabolism. - Fluconazole: possible increase in mycophenolate levels.